Free Trial
Louis Chen

Louis Chen Analyst Performance

Managing Director at Scotiabank

Louis Chen is a stock analyst at Scotiabank in the medical sector, covering 2 publicly traded companies. Over the past year, Louis Chen has issued 4 stock ratings, including strong buy, buy, and hold recommendations. While full access to Louis Chen's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Louis Chen's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions.

Analyst Rankings, Coverage, and Performance Statistics

Average Return
00.00% 12-Month ROI
Success Rate
00.00% Profitable Ratings
Total Ratings
4 Last 0 Years
Buy Recommendations
75.00% 3 Buy Ratings
Companies Covered
2 Unique Companies

Ratings Distribution

RatingPercentageCount
Strong Buy25.0%1 ratings
Buy50.0%2 ratings
Hold25.0%1 ratings
Sell0.0%0 ratings

Out of 4 total stock ratings issued by Louis Chen at Scotiabank, the majority (50.0%) have been Buy recommendations, followed by 25.0% Strong Buy and 25.0% Hold.

Best & Worst Calls

This analyst does not have any ratings with enough history to determine best and worst calls.

Exchange Coverage

ExchangePercentageCount
NASDAQ
50.0% of companies on NASDAQ
1 company
NYSE
50.0% of companies on NYSE
1 company

Louis Chen, an analyst at Scotiabank, currently covers 2 companies listed on NASDAQ and NYSE, with the majority traded on NASDAQ.

Coverage Focus

Sector IconSectorPercentage
Medical
2 companies
100.0%

Louis Chen of Scotiabank specializes in stock coverage within the Medical sector.

Coverage Industries

IndustryPercentage
MED - BIOMED/GENE
2 companies
100.0%

Louis Chen's Ratings History at Scotiabank

Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.
Available with a MarketBeat All Access Subscription
12-Month ROIUpgrade to All Access to use the All ROI Filter
CompanyReport DateActionReport Date Price12-Month
Price Target
Rating12-Month
Price & ROI
Details
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
2/11/2026Boost Price Target$147.23$177.00Sector Outperform
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
12/4/2025Reiterated Rating$50.97$53.00Sector Perform
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
11/13/2025Initiated Coverage$123.40$140.00Sector Outperform
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
11/12/2025Upgrade$125.20Strong-Buy